References
- Abdelkader H, Pierscionek B, Alany RG. (2014). Novel in situ gelling ocular films for the opioid growth factor-receptor antagonist-naltrexone hydrochloride: fabrication, mechanical properties, mucoadhesion, tolerability and stability studies. Int J Pharm 477:631–42.
- Balguri SP, Adelli GR, Tatke A, et al. (2017). Melt-cast noninvasive ocular inserts for posterior segment drug delivery. J Pharm Sci 106:3515–23.
- Botelho TDS, Rebello Lourenco F, Pinto TDJA. (2013). Vancomycin microbial assay using kinetic-reading microplate system. Curr Pharm Anal 9:172–6.
- Castro PM, Baptista P, Madureira AR, et al. (2018). Combination of PLGA nanoparticles with mucoadhesive guar-gum films for buccal delivery of antihypertensive peptide. Int J Pharm 547:593–601.
- Cheng C, Liu S, Xiao D, et al. (2010). LC-MS/MS method development and validation for the determination of polymyxins and vancomycin in rat plasma. J Chromatogr B Anal Technol Biomed Life Sci 878:2831–8.
- Chiou GC, Li BH. (1993). Chronic systemic delivery of insulin through the ocular route. J Ocular Pharm 9:85–90.
- de Andrade GC, Ventura CV, Mello Filho PA, et al. (2017). Arboviruses and the eye. Int J Retina Vitreous 3:4.
- Du QS, Xie NZ, Huang RB. (2015). Recent development of peptide drugs and advance on theory and methodology of peptide inhibitor design. Med Chem 11:235–47.
- Elyasi S, Khalili H, Dashti-Khavidaki S, et al. (2012). Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review. Eur J Clin Pharmacol 68:1243–55.
- Fangueiro JF, Veiga F, Silva AM, et al. (2016). Ocular drug delivery - new strategies for targeting anterior and posterior segments of the eye. Curr Pharm Design 22:1135–46.
- Hagihara M, Sutherland C, Nicolau DP. (2013). Development of HPLC methods for the determination of vancomycin in human plasma, mouse serum and bronchoalveolar lavage fluid. J Chromatogr Sci 51:201–7.
- Healy VL, Lessard IA, Roper DI, et al. (2000). Vancomycin resistance in enterococci: reprogramming of the D-ala-D-Ala ligases in bacterial peptidoglycan biosynthesis. Chem Biol 7:R109–119.
- Jain A, Jain A, Gulbake A, et al. (2013). Peptide and protein delivery using new drug delivery systems. Crit Rev Ther Drug Carrier Syst 30:293–329.
- Jorgensen L, Moeller EH, Weert MVD, et al. (2006). Preparing and evaluating delivery systems for proteins. Eur J Pharm Sci 29:174–82.
- Kumar A, Tiwari BK, Kumar S. (2018). Evaluation of ocular films of ofloxacin for antibacterial activity. Int J Appl Pharm 10:275–6.
- Mitragotri S, Burke PA, Langer R. (2014). Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat Rev Drug Discov 13:655–72.
- Pawar K, Kolli CS, Rangari VK, Babu RJ. (2017). Transdermal iontophoretic delivery of lysine-proline-valine (KPV) peptide across microporated human skin. J Pharm Sci 106:1814–20.
- Pringels E, Callens C, Vervaet C, et al. (2006). Influence of deposition and spray pattern of nasal powders on insulin bioavailability. Int J Pharm 310:1–7.
- Rahhal TB, Fromen CA, Wilson EM, et al. (2016). Pulmonary delivery of butyrylcholinesterase as a model protein to the lung. Mol Pharm 13:1626–35.
- Ramsay E, del Amo EM, Toropainen E, et al. (2018). Corneal and conjunctival drug permeability: systematic comparison and pharmacokinetic impact in the eye. Eur J Pharm Sci 119:83–9.
- Ranta VP, Mannermaa E, Lummepuro K, et al. (2010). Barrier analysis of periocular drug delivery to the posterior segment. J Control Release 148:42–8.
- Sarmento B. (2010). Nanomedicines for delivery of therapeutic proteins and biopharmaceuticals. Ther Deliv 1:231–5.
- Sinha VR, Trehan A. (2003). Biodegradable microspheres for protein delivery. J Control Release 90:261–80.
- Soni V, Singh R, Srinivasan R, et al. (1998). Pulsatile insulin delivery through the ocular route. Drug Deliv 5:47–51.
- Srinivasarao DA, Lohiya G, Katti DS. (2019). Fundamentals, challenges, and nanomedicine‐based solutions for ocular diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol 11:1548–74.
- Sullivan BP, El-Gendy N, Kuehl C, Berkland C. (2015). Pulmonary delivery of vancomycin dry powder aerosol to intubated rabbits. Mol Pharm 12:2665–74.
- Theodossiadis PG, Markomichelakis NN, Sfikakis PP. (2007). Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation. Retina (Philadelphia, Pa.) 27:399–413.
- Uhl P, Pantze S, Storck P, et al. (2017). Oral delivery of vancomycin by tetraether lipid liposomes. Eur J Pharm Sci 108:111–8.
- Villena R, González CA, Nalegach ME, et al. (2014). Therapeutic monitoring of intravenous vancomycin in a pediatric critical care unit. Revista Chilena de Infectología 31:249–53.
- Wickham M, Faulks R, Mills C. (2009). In vitro digestion methods for assessing the effect of food structure on allergen breakdown. Mol Nutr Food Res 53:952–8.
- Yeo KT, Traverse W, Horowitz GL. (1989). Clinical performance of the EMIT vancomycin assay. Clin Chem 35:1504–7.
- Yousry C, Elkheshen SA, El-Laithy HM, et al. (2017). Studying the influence of formulation and process variables on vancomycin-loaded polymeric nanoparticles as potential carrier for enhanced ophthalmic delivery. Eur J Pharm Sci 100:142–54.
- Zhang Y, Chen Y, Yu X, et al. (2016). A flexible device for ocular iontophoretic drug delivery. Biomicrofluidics 10:011911